Precedent

Venom-derived drugs are already approved

Regulatory pathway proven. Commercial potential validated. T-Hawk is not asking the FDA to accept a new idea. Only a new source.

FDA / EMA-approved drugs derived from animal venom
Brazilian lancehead pit viper, the source organism for Captopril.
From the Brazilian lancehead pit viper

Captopril

The first venom-derived drug. An ACE inhibitor for hypertension, and the proof that a peptide from a bite could become a blockbuster.

Pygmy rattlesnake, the source organism for Eptifibatide.
From the Pygmy rattlesnake

Eptifibatide

An antiplatelet agent used in acute coronary syndrome, engineered directly from a venom peptide motif.

Gila monster, the source organism for Exenatide.
From the Gila monster

Exenatide

GLP-1 proof of concept. A lizard venom peptide became the foundation of an entire metabolic drug class.

Medicinal leech, the source organism for Bivalirudin.
From the Medicinal leech

Bivalirudin

A direct thrombin inhibitor derived from hirudin, used during percutaneous coronary intervention.

Arizona bark scorpion, the source organism for Anascorp.
From the Arizona bark scorpion

Anascorp

An FDA-approved scorpion antivenom, developed from a Sonoran Desert species, in Arizona.

Cone snail, the source organism for Ziconotide.
From the Cone snail

Ziconotide

A selective CaV2.2 (N-type calcium channel) blocker for severe chronic pain. Non-opioid, non-addictive, and the closest published analogue to T-Hawk's CaV2.2 candidates.

Read the last card again. Ziconotide is a selective CaV2.2 blocker from a marine snail: a venom peptide that treats severe pain without an opioid mechanism. It works, it is approved, and it validates the exact channel class T-Hawk's CaV2.2 candidates address, from Arthropods that live footsteps from the lab. See the pipeline.
What the precedent establishes

Regulatory

Venom-derived peptides have cleared FDA and EMA review across cardiology, metabolic disease, toxicology, and pain. The path is mapped.

Commercial

These molecules built markets. One of them seeded the GLP-1 class. Payers and partners already understand the category.

Local

Anascorp came out of an Arizona species and Arizona institutions. The Sonoran Desert has produced an approved product before.